| Species |
Human |
| Protein Construction |
CD19 (Pro20-Lys291)
Accession # P15391 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Expression System |
CHO |
| Apparent Molecular Weight |
~62 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD19 is a 95 kDa coreceptor, which amplifies the signaling cascade in B cells. On the B cell surface, CD19 associates with CD21, CD81 and Leu-13 to exert its function. The cytoplasmic tail of CD19 has nine conserved tyrosine residues playing critical roles in CD19 mediated function by coupling signaling molecules to the receptor. Mature human CD19 consists of a 272aa extracellular domain (ECD) with two Ig-like domains, a 22aa transmembrane segment, and a 243aa cytoplasmic domain. |
| Synonyms |
CD19; Leu-12; B4; B-lymphocyte antigen |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
